OKI-219

Phase 1Small molecule

OOnKure, Inc.

OKI-219 is one of 34 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Advanced CancerActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Advanced CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Advanced Cancer

NCT06239467

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

Active, not recruiting·OOnKure, Inc.·Phase 1·NCT06239467·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OKI-219. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OKI-219 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OKI-219. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OnKure, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOnKure, Inc.

OKI-219

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News